Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

Excluding contributions from compounded semaglutide, Hims & Hers said it expects it weight loss offering will generate at least $725 million in revenue in 2025. Hims & Hers also offers treatments ...

"Our aim at Hims and Hers is to build a robust platform that's able to treat multiple specialties; our aim is not to necessarily just be a weight-loss company," Okupe explains. Regarding ...

Now, the real test begins for Hims. The company poured millions into marketing$16 million alone on a Super Bowl adand built its growth story around weight loss. But with GLP-1 sales vanishing ...

Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...